




RealRate

PHARMACEUTICAL 2022

Matinas BioPharma Holdings Inc.
Rank 250 of 475

MATINAS
BIOPHARMA



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -107%, being 169% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	50,993
Cost of Goods Sold	0
Intangible Assets	4,354
Liabilities, Current	4,349
Liabilities, Non-Current	4,484
Other Assets	4,441
Other Compr. Net Income	-374
Other Expenses	0
Other Liabilities	0
Other Net Income	1,328
Property and Equipment	1,538
Research and Development	14,583
Revenues	156
Selling, General and Administrative Expense	10,185

Output Variable	Value in 1000 USD
Assets	61,326
Liabilities	8,833
Expenses	24,768
Stockholders Equity	52,493
Net Income	-23,283
Comprehensive Net Income	-23,470
Economic Capital Ratio	-107%